x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011816
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human ATP2A2/SERCA2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ATP2A2 |
| UniProt No. | P16615 |
| Gene ID | 488 |
| Gene Description | The ATP2A2 calcium pump is one of several sarcoplasmic and endoplasmic reticulum Ca2+-ATPases responsible for regulating calcium transport across intracellular membranes. Multiple isoforms have been isolated, with ATP2A2a found predominantly in the sarcoplasmic reticulum of muscle cells and ATP2A2b more ubiquitously expressed in the endoplasmic reticulum of most cell types. An isoform containing a truncated carboxy region is expressed in epithelial and hematopoietic cell lines and may be involved in monocyte differentiation. Post-translational modification of ATP2A2, including phosphorylation and tyrosine nitration, modify Ca2+ -ATPase activity and calcium transport. Mutation in the corresponding ATP2A2 gene results in Darier disease, a skin disorder characterized by the presence of dark, keratotic papules or rash found on the head and torso. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
